Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Clostridioides difficile spore antigens are a complex array of proteins and glycoproteins located on the outermost layers of the bacterial spore, specifically the spore coat and the exosporium (Paredes-Sabja, D., et al., 2014). These antigens, including BclA1, CdeC, CdeM, and various Cot proteins, are essential for the spore's structural integrity and its ability to survive extreme environmental conditions and gastric acid (Calderón-Romero, P., et al., 2018). In the context of infection, these surface components facilitate the initial adherence of spores to the host's intestinal epithelium, a critical step for colonization (Barra-Carrasco, J., & Paredes-Sabja, D., 2014). Furthermore, specific antigens are involved in sensing environmental cues that trigger germination into the vegetative, toxin-producing state that causes clinical disease (Zhu, D., et al., 2018). Because spores are resistant to standard antibiotics and are responsible for high rates of disease recurrence, these antigens have become primary targets for the development of vaccines and monoclonal antibodies. Therapeutic strategies focusing on these antigens aim to enhance the host's immune clearance of spores via opsonophagocytosis or to physically prevent the spores from adhering and germinating within the gut (Paredes-Sabja, D., et al., 2014).
Induction of opsonophagocytic antibodies to facilitate immune-mediated clearance of spores, blocking of spore-host cell interactions to prevent colonization, and interference with the signaling pathways required for spore germination (Paredes-Sabja, D., et al., 2014; Zhu, D., et al., 2018).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Clostridioides difficile spore antigens (C. difficile spore antigens).